



## **Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018**

May 3, 2018

SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under "News & Events" in the "Investors" section of the Company's website at <http://www.iovance.com/> or you may use the link: <https://edge.media-server.com/m6/p/ouykqu6a>.

A replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics' website at <http://www.iovance.com/>.

### **About Iovance Biotherapeutics, Inc.**

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit <http://www.iovance.com>.

### **Investor Contact:**

Sarah McCabe  
Stern Investor Relations, Inc.  
212-362-1200  
[sarah@sternir.com](mailto:sarah@sternir.com)

### **Media Contact:**

Evan Smith  
FTI Consulting  
212-850-5622  
[evan.smith@fticonsulting.com](mailto:evan.smith@fticonsulting.com)



Iovance Biotherapeutics, Inc.